Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by South Dakota Investment Council

South Dakota Investment Council boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 26.5% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 12,802 shares of the biopharmaceutical company’s stock after acquiring an additional 2,683 shares during the quarter. South Dakota Investment Council’s holdings in Regeneron Pharmaceuticals were worth $7,198,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in REGN. Brighton Jones LLC boosted its holdings in Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $226,000. World Investment Advisors grew its stake in Regeneron Pharmaceuticals by 51.7% in the 2nd quarter. World Investment Advisors now owns 549 shares of the biopharmaceutical company’s stock valued at $288,000 after acquiring an additional 187 shares during the period. Hantz Financial Services Inc. increased its stake in shares of Regeneron Pharmaceuticals by 68.8% during the second quarter. Hantz Financial Services Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 44 shares in the last quarter. Finally, Telos Capital Management Inc. purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $253,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 3.1%

Shares of Regeneron Pharmaceuticals stock opened at $766.66 on Wednesday. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The stock has a market cap of $81.05 billion, a price-to-earnings ratio of 18.45, a PEG ratio of 2.12 and a beta of 0.41. The company has a fifty day simple moving average of $771.45 and a 200-day simple moving average of $685.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $12.07 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be paid a dividend of $0.94 per share. The ex-dividend date is Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the transaction, the director owned 17,803 shares in the company, valued at $13,860,169.59. The trade was a 0.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 5,274 shares of company stock worth $4,142,738. Corporate insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on REGN shares. Evercore lifted their target price on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research note on Thursday, January 22nd. HSBC assumed coverage on Regeneron Pharmaceuticals in a research report on Monday, November 24th. They issued a “buy” rating and a $255.00 price objective for the company. Wells Fargo & Company lifted their price target on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Zacks Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Finally, Royal Bank Of Canada lifted their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $796.52.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.